[go: up one dir, main page]

DK1651234T3 - Kombination af en mglur2-antagonist og ache-inhibitor til behandling af akutte og/eller kroniske neurologiske lidelser - Google Patents

Kombination af en mglur2-antagonist og ache-inhibitor til behandling af akutte og/eller kroniske neurologiske lidelser

Info

Publication number
DK1651234T3
DK1651234T3 DK04741126T DK04741126T DK1651234T3 DK 1651234 T3 DK1651234 T3 DK 1651234T3 DK 04741126 T DK04741126 T DK 04741126T DK 04741126 T DK04741126 T DK 04741126T DK 1651234 T3 DK1651234 T3 DK 1651234T3
Authority
DK
Denmark
Prior art keywords
acute
treatment
combination
neurological disorders
chronic neurological
Prior art date
Application number
DK04741126T
Other languages
Danish (da)
English (en)
Inventor
Theresa Maria Ballard
Mcarthur Silvia Gatti
Erwin Goetschi
Juergen Wichmann
Thomas Johannes Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34130033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1651234(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1651234T3 publication Critical patent/DK1651234T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK04741126T 2003-07-25 2004-07-17 Kombination af en mglur2-antagonist og ache-inhibitor til behandling af akutte og/eller kroniske neurologiske lidelser DK1651234T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03016968 2003-07-25
PCT/EP2004/008020 WO2005014002A1 (en) 2003-07-25 2004-07-17 Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders

Publications (1)

Publication Number Publication Date
DK1651234T3 true DK1651234T3 (da) 2008-01-28

Family

ID=34130033

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04741126T DK1651234T3 (da) 2003-07-25 2004-07-17 Kombination af en mglur2-antagonist og ache-inhibitor til behandling af akutte og/eller kroniske neurologiske lidelser

Country Status (27)

Country Link
US (1) US7235547B2 (es)
EP (1) EP1651234B1 (es)
JP (1) JP5005343B2 (es)
KR (1) KR100764330B1 (es)
CN (1) CN1856312A (es)
AR (1) AR045926A1 (es)
AT (1) ATE374030T1 (es)
AU (1) AU2004262897B9 (es)
BR (1) BRPI0412919A (es)
CA (1) CA2532347C (es)
CO (1) CO5640124A2 (es)
DE (1) DE602004009195T2 (es)
DK (1) DK1651234T3 (es)
ES (1) ES2293287T3 (es)
HR (1) HRP20070552T3 (es)
IL (1) IL173131A (es)
MX (1) MXPA06000705A (es)
MY (1) MY138394A (es)
NO (1) NO20060328L (es)
NZ (1) NZ544719A (es)
PL (1) PL1651234T3 (es)
PT (1) PT1651234E (es)
RU (1) RU2357734C2 (es)
SI (1) SI1651234T1 (es)
TW (1) TW200524614A (es)
WO (1) WO2005014002A1 (es)
ZA (1) ZA200600693B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US20050222175A1 (en) * 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7488736B2 (en) * 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7576211B2 (en) * 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
US7407966B2 (en) * 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7598265B2 (en) * 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
WO2010065743A2 (en) * 2008-12-03 2010-06-10 Nanotherapeutics, Inc. Bicyclic compounds and methods of making and using same
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8541404B2 (en) * 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
RU2472475C2 (ru) * 2010-04-20 2013-01-20 Учреждение образования "Белорусский государственный медицинский университет" (УО БГМУ) Способ комбинированного лечения глаукомной оптической нейропатии
KR20150070187A (ko) 2012-10-23 2015-06-24 에프. 호프만-라 로슈 아게 자폐 장애의 치료를 위한 ｍｇｌｕ２／３ 길항제
KR20160143853A (ko) 2014-04-23 2016-12-14 에프. 호프만-라 로슈 아게 지적 장애의 치료를 위한 mglu2/3 길항제
CN112462047B (zh) * 2020-11-13 2023-02-07 北京元恩生物技术有限公司 一种尼卡巴嗪检测试剂盒及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
DK1089976T3 (da) * 1998-06-22 2004-01-19 Neurosearch As Fremgangsmåde til fremstilling af 5-bromisoquinolin og dets 8-nitroderivat
US6194403B1 (en) * 1999-09-09 2001-02-27 Unitech Pharmaceuticals, Inc. Tacrine derivatives for treating Alzheimer's disease
PL357433A1 (en) * 1999-10-15 2004-07-26 F.Hoffmann-La Roche Ag Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
HRP20020259A2 (en) * 1999-10-15 2004-04-30 Hoffmann La Roche Benzodiazepine derivatives
CA2310926C (en) * 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
EP1203584A1 (en) 2000-10-13 2002-05-08 M.D.M. S.r.l. Cholinergic precursor (in particular choline alfoscerate) associated with an acetylcholinesterase inhibitor (such as rivastigmine, donepezil)
US6500972B2 (en) * 2001-01-03 2002-12-31 Chinese Petroleim Corp. Synthesis of TMBQ with transition metal-containing molecular sieve as catalysts
US6500955B1 (en) * 2001-02-02 2002-12-31 National Institute Of Pharmaceutical Education And Research One pot synthesis of [2,8-Bis (trifluoromethyl)-4-quinolinyl]-2-pyridinylmethanone, a mefloquine intermediate
EP1377640B1 (en) * 2001-04-09 2017-05-17 FUJIFILM Corporation Azo compounds and process of producing the same and novel intermediate compounds used in the process of producing azo compounds
YU79103A (sh) * 2001-04-12 2006-05-25 F. Hoffmann-La Roche Ag. Derivati dihidro-benzo/b/ /1,4/diazepin-2-ona kao antagonisti mglur2 i receptora
IL157873A0 (en) * 2001-04-12 2004-03-28 Hoffmann La Roche DIHYDRO-BENZO [b] [1,4] DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II
US6949542B2 (en) * 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives

Also Published As

Publication number Publication date
US20050049243A1 (en) 2005-03-03
IL173131A0 (en) 2006-06-11
DE602004009195D1 (de) 2007-11-08
AU2004262897B9 (en) 2009-12-17
JP5005343B2 (ja) 2012-08-22
BRPI0412919A (pt) 2006-09-26
EP1651234B1 (en) 2007-09-26
CA2532347C (en) 2012-03-27
RU2006105721A (ru) 2007-09-10
RU2357734C2 (ru) 2009-06-10
KR20060037404A (ko) 2006-05-03
NO20060328L (no) 2006-02-17
TW200524614A (en) 2005-08-01
US7235547B2 (en) 2007-06-26
AU2004262897B2 (en) 2009-08-20
IL173131A (en) 2010-12-30
CN1856312A (zh) 2006-11-01
KR100764330B1 (ko) 2007-10-05
ZA200600693B (en) 2007-05-30
ATE374030T1 (de) 2007-10-15
CA2532347A1 (en) 2005-02-17
CO5640124A2 (es) 2006-05-31
AU2004262897A1 (en) 2005-02-17
SI1651234T1 (sl) 2008-02-29
MXPA06000705A (es) 2006-04-11
NZ544719A (en) 2009-04-30
HRP20070552T3 (en) 2008-05-31
EP1651234A1 (en) 2006-05-03
ES2293287T3 (es) 2008-03-16
AR045926A1 (es) 2005-11-16
MY138394A (en) 2009-05-29
DE602004009195T2 (de) 2008-06-26
JP2007504096A (ja) 2007-03-01
PT1651234E (pt) 2007-12-28
PL1651234T3 (pl) 2008-02-29
WO2005014002A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
DK1651234T3 (da) Kombination af en mglur2-antagonist og ache-inhibitor til behandling af akutte og/eller kroniske neurologiske lidelser
DK1663978T3 (da) Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
DK1487541T3 (da) Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelse af perifere vaskulære sygdomme
CY2013042I1 (el) Αναστολεις πυριδυλιου της σηματοδοτησης hedgehog
DK2084151T3 (da) Substituerede dihydropyrazoloner til behandling af kardiovaskulære og hæmatologiske sygdomme
DK1745041T3 (da) Quinoxalin-inhibitorer af hedgehog-signaleringsvejen
DK1824475T3 (da) Fremgangsmåde til oprensning af trans-(-)-delta9-tetrahydrocannabinol og trans-(+)-delta9-tetrahydrocannabinol
DK1592686T3 (da) Gyrase-inhibitorer og anvendelser deraf
DK2075000T3 (da) Kombination af azelastin og ciclesonid
ATE505471T1 (de) Azaindol-kinaseinhibitoren
DK1474416T3 (da) Dihydrobenzodiazepin-2-on-derivater til behandlingen af neurologiske lidelser
EP2051394A4 (en) HIGH FREQUENCY COMPONENT AND HIGH FREQUENCY CIRCUIT FOR USE THEREIN
EP1931691A4 (en) ODKASE INHIBITORS FOR THE TREATMENT OF MALARIA
BRPI0719519A2 (pt) Sistemas de descarga e métodos de utilização dos mesmos
EP1660436A4 (en) cathepsin inhibitors
DK1278540T3 (da) Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelsen af aterosklerose
DK1536796T3 (da) N-arylpiperidinsubstituerede biphenylcarboxamider som inhibitorer af apolipoprotein B-sektion
MA27395A1 (fr) Utilisation de prebiotiques pour le traitement et la prevention des syndromes hyper-glycemiques
DK1599469T3 (da) Tetrazolderivater og fremgangsmåder til behandling af metabolismerelaterede forstyrrelser dermed
EP1613311A4 (en) HIF-1 INHIBITORS
ATE499096T1 (de) Kombination von serotonin-wiederaufnahme-hemmern und agomelatin
NO20054913D0 (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
EP1772148A4 (en) Lipase inhibitors
EP1767204A4 (en) LIPASE INHIBITORS
EP1697331A4 (en) INHIBITORS OF MITOTIC KINESINE